Tags

Type your tag names separated by a space and hit enter

Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.
BMC Infect Dis. 2006 Jul 11; 6:107.BI

Abstract

BACKGROUND

Antiretroviral treatment (ART) in children has special features and consequently, results obtained from clinical trials with antiretroviral drugs in adults may not be representative of children. Nelfinavir (NFV) is an HIV-1 Protease Inhibitor (PI) which has become as one of the first choices of PI for ART in children. We studied during a 3-year follow-up period the effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children.

METHODS

Forty-two vertically HIV-infected children on HAART with NFV were involved in a multicentre prospective study. The children were monitored at least every 3 months with physical examinations, and blood sample collection to measure viral load (VL) and CD4+ cell count. We performed a logistic regression analysis to determinate the odds ratio of baseline characteristics on therapeutic failure.

RESULTS

Very important increase in CD4+ was observed and VL decreased quickly and it remained low during the follow-up study. Children with CD4+ <25% at baseline achieved CD4+ >25% at 9 months of follow-up. HIV-infected children who achieved undetectable viral load (uVL) were less than 40% in each visit during follow-up. Nevertheless, HIV-infected children with VL >5000 copies/ml were less than 50% during the follow-up study. Only baseline VL was an important factor to predict VL control during follow-up. Virological failure at defined end-point was confirmed in 30/42 patients. Along the whole of follow-up, 16/42 children stopped HAART with NFV. Baseline characteristics were not associated with therapeutic change.

CONCLUSION

NFV is a safe drug with a good profile and able to achieve an adequate response in children.

Authors+Show Affiliations

Laboratorio de Inmuno-Biología Molecular, Hospital General Universitario Gregorio Marañón, Madrid, Spain. sresino.hgugm@salud.madrid.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16834769

Citation

Resino, Salvador, et al. "Effects of Highly Active Antiretroviral Therapy With Nelfinavir in Vertically HIV-1 Infected Children: 3 Years of Follow-up. Long-term Response to Nelfinavir in Children." BMC Infectious Diseases, vol. 6, 2006, p. 107.
Resino S, Larrú B, Maria Bellón J, et al. Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children. BMC Infect Dis. 2006;6:107.
Resino, S., Larrú, B., Maria Bellón, J., Resino, R., de José, M. I., Navarro, M., Léon, J. A., Ramos, J. T., Mellado, M. J., & Muñoz-Fernández, M. A. (2006). Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children. BMC Infectious Diseases, 6, 107.
Resino S, et al. Effects of Highly Active Antiretroviral Therapy With Nelfinavir in Vertically HIV-1 Infected Children: 3 Years of Follow-up. Long-term Response to Nelfinavir in Children. BMC Infect Dis. 2006 Jul 11;6:107. PubMed PMID: 16834769.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children. AU - Resino,Salvador, AU - Larrú,Beatriz, AU - Maria Bellón,Jose, AU - Resino,Rosa, AU - de José,Maria Isabel, AU - Navarro,Marisa, AU - Léon,Juan Antonio, AU - Ramos,José Tomás, AU - Mellado,Maria José, AU - Muñoz-Fernández,Maria Angeles, Y1 - 2006/07/11/ PY - 2006/04/05/received PY - 2006/07/11/accepted PY - 2006/7/13/pubmed PY - 2006/9/28/medline PY - 2006/7/13/entrez SP - 107 EP - 107 JF - BMC infectious diseases JO - BMC Infect Dis VL - 6 N2 - BACKGROUND: Antiretroviral treatment (ART) in children has special features and consequently, results obtained from clinical trials with antiretroviral drugs in adults may not be representative of children. Nelfinavir (NFV) is an HIV-1 Protease Inhibitor (PI) which has become as one of the first choices of PI for ART in children. We studied during a 3-year follow-up period the effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children. METHODS: Forty-two vertically HIV-infected children on HAART with NFV were involved in a multicentre prospective study. The children were monitored at least every 3 months with physical examinations, and blood sample collection to measure viral load (VL) and CD4+ cell count. We performed a logistic regression analysis to determinate the odds ratio of baseline characteristics on therapeutic failure. RESULTS: Very important increase in CD4+ was observed and VL decreased quickly and it remained low during the follow-up study. Children with CD4+ <25% at baseline achieved CD4+ >25% at 9 months of follow-up. HIV-infected children who achieved undetectable viral load (uVL) were less than 40% in each visit during follow-up. Nevertheless, HIV-infected children with VL >5000 copies/ml were less than 50% during the follow-up study. Only baseline VL was an important factor to predict VL control during follow-up. Virological failure at defined end-point was confirmed in 30/42 patients. Along the whole of follow-up, 16/42 children stopped HAART with NFV. Baseline characteristics were not associated with therapeutic change. CONCLUSION: NFV is a safe drug with a good profile and able to achieve an adequate response in children. SN - 1471-2334 UR - https://www.unboundmedicine.com/medline/citation/16834769/Effects_of_highly_active_antiretroviral_therapy_with_nelfinavir_in_vertically_HIV_1_infected_children:_3_years_of_follow_up__Long_term_response_to_nelfinavir_in_children_ L2 - https://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-2334-6-107 DB - PRIME DP - Unbound Medicine ER -